The production of the Alzheimer’s-associated, toxic protein amyloid beta in the brain is tightly regulated by cholesterol in the cell membrane, advanced imaging reveals.
News Archives ⋆ Phytocopeia
Why can some people weather the stress of social isolation better than others, and what implications does this have for their health? New research found that people who felt a strong sense of purpose in life were less lonely during the COVID-19 pandemic.
Scientists explore how protein and signaling pathways change in patients with Alzheimer’s disease. Their work creates a new model of disease progression, taking advantage of the heterogeneity that is inherent to human studies.
A new study not only sheds light on how the APOE4 gene may cause some of the pathologies associated with Alzheimer’s disease, but also suggests a new treatment target that might help people who carry the APOE4 gene in early and late stages of the disease. Researchers found that APOE4 is associated with the activation of an inflammatory protein that causes a breakdown in the blood-brain barrier which protects the brain.
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer’s disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.
The team looked in different regions of the brain, which are affected in Alzheimer’s disease before looking for common changes across these cortical regions. They identified 220 sites in the genome, including 84 new genes, which showed different levels of DNA methylation in the cortex in individuals with more severe Alzheimer’s disease, which weren’t seen in the cerebellum.
A study of nearly 2,500 adults found that having trouble falling asleep, as compared to other patterns of insomnia, was the main insomnia symptom that predicted cognitive impairment 14 years later.
A new study of over 3000 people, has shown for the first time that a single biomarker can accurately indicate the presence of underlying neurodegeneration in people with cognitive issues.